Choose Your Country or Region

Ruxolitinib Phosphate

Name: Ruxolitinib Phosphate
Brand: Selleck Chemicals
SKU: S5243
Rating: 5 (163 reviews)

Catalog No.S5243 Synonyms: INCB018424, INC424

For research use only.

Ruxolitinib Phosphate (INCB018424, INC424) is the phosphate salt form of Ruxolitinib. Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.

Ruxolitinib Phosphate Chemical Structure

CAS No. 1092939-17-7

Selleck's Ruxolitinib Phosphate has been cited by 163 publications

Purity & Quality Control

Choose Selective JAK Inhibitors

Related Compound Libraries

Other JAK Products

FLLL32^New

FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.
Cerdulatinib (PRT062070) hydrochloride^New

Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
Ruxolitinib (INCB018424)

Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.
Tofacitinib (CP-690550) Citrate

Tofacitinib citrate (CP-690550, Tasocitinib) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively. Tofacitinib citrate has anti-infection activity.
Tofacitinib (CP-690550)

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.
AZD1480

AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.
Fedratinib (TG101348)

Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Fedratinib also inhibits FMS-like tyrosine kinase 3 (FLT3) and RET (c-RET) with IC50 of 15 nM and 48 nM, respectively. Fedratinib has potential antineoplastic activity. Fedratinib inhibits proliferation and induces apoptosis. Phase 2.
Momelotinib (CYT387)

Momelotinib (CYT387, LM-1149 , CYT11387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Momelotinib (CYT387) induces apoptosis and autophagy. Phase 3.
WP1066

WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. WP1066 induces apoptosis. Phase 1.

Download Inhibitor Catalog

JAK Signaling Pathway Map

Biological Activity

Description

Targets

JAK2 ^[1] (Cell-free assay)	JAK1 ^[1] (Cell-free assay)
2.8 nM	3.3 nM

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Sf21	MofISpVv[3Srb36gZZN{[Xl?		MU[xJIhz	MUjJcohq[mm2aX;uJI9nKGi3bXHuJGpCUzJia3nuZZNmKGSxbXHpckBmgHC{ZYPz[YQhcW5iU3[yNUBk\WyuczD1d4lv\yCHUVXESXBGT0S\RlXXUGUh[XNic4Xid5Rz[XSnIHHmeIVzKDFiaIKgZpkhUFSURjDhd5NigSxiSVO1NF0xNjByMklOwG0>	NEL5[XI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW5NVQxOid-MkK1PVE1ODJ:L3G+
Sf21	MnexSpVv[3Srb36gZZN{[Xl?		MV6xJIhz	M1TyVWlvcGmkaYTpc44hd2ZiaIXtZY4hUkGNMTDrbY5ie2ViZH;tZYlvKGW6cILld5Nm\CCrbjDT[lIyKGOnbHzzJJV{cW6pIFXRSWRGWEWJRGnGSXdNTSCjczDzeYJ{fHKjdHWgZYZ1\XJiMTDodkBjgSCKVGLGJIF{e2G7LDDJR\|UxRTBwMECzN:69VQ>?	NIfVeow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW5NVQxOid-MkK1PVE1ODJ:L3G+
Sf21	MoLzSpVv[3Srb36gZZN{[Xl?		M2m3XlEhcHJ?	MonTTY5pcWKrdHnvckBw\iCqdX3hckBVYUt{IHvpcoF{\SCmb33hbY4h\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgeZNqdmdiRWHFSGVRTUeGWV\FW2xGKGG\|IIP1ZpN1emG2ZTDh[pRmeiBzIHjyJIJ6KEiWUl[gZZN{[XluIFnDOVA:OC5yMUpOwG0>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV7MUSwNkc,OjJ3OUG0NFI9N2F-
Sf21	MYTGeY5kfGmxbjDhd5NigQ>?		MWCxJIhz	NX\xeGFSUW6qaXLpeIlwdiCxZjDoeY1idiCMQVuzJItqdmG\|ZTDkc41icW5iZYjwdoV{e2WmIHnuJHNnOjFiY3XscJMhfXOrbnegSXFGTEWSRVfEXWZGX0yHIHHzJJN2[nO2cnH0[UBi\nSncjCxJIhzKGK7IFjUVmYh[XO\|YYmsJGlEPTB;MD60NljPxE1?	NGXQS3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW5NVQxOid-MkK1PVE1ODJ:L3G+
TF1	MkDJSpVv[3Srb36gZZN{[Xl?		NGfINnczOCCvaX7z	NUCx[ZlyUW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEWSTz3pcoR2[2WmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNicILpc5IhfG9iRWDPMYlv\HWldHnvckBu\WG\|dYLl[EBi\nSncjCzNEB1dyB2NTDtbY5{NCCHQ{WwQVAvODF{zszN	M{nKelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nkm4NFg1Lz5{Mk[5PFA5PDxxYU6=
TF1	NUXvfIRKTnWwY4Tpc44h[XO\|YYm=		MXyyNEBucW6\|	NF\IVJFKdmirYnn0bY9vKG:oIFrBT\|EhcW5iaIXtZY4hXEZzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhUUx4LXnu[JVk\WRiU2TBWFMheGixc4Doc5J6dGG2aX;uJIlv[3WkYYTl[EBnd3JiMkCgcYlveyCycnnvdkB1dyCLTE[tbY5lfWO2aX;uJI1m[XO3cnXkJIFnfGW{IEOwJJRwKDR3IH3pcpMtKEWFNUC9NE4xOjUQvF2=	NHm1[Zg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[5PFA5PCd-MkK2PVgxQDR:L3G+
SET2	NFPMdmtHfW6ldHnvckBie3OjeR?=			NUjE[odQUW6qaXLpeIlwdiCxZjDKRWszKFZ4MUfGJI12fGGwdDDpckBpfW2jbjDTSXQzKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDTWGFVPSCyaH;zdIhwenmuYYTpc44tKEmFNUC9NE4xODF6NN88US=>	M3rQSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xOlYxLz5{M{C2NVY3ODxxYU6=
TF1	MXHGeY5kfGmxbjDhd5NigQ>?		NFvJTGY{OCCvaX7z	MUPJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDTWGFVPSCyaH;zdIhwenmuYYTpc44hcW6ldXLheIVlKG[xcjCzNEBucW6\|IHnuJJBz\XOnbnPlJI9nKGi3bXHuJJJm[2:vYnnuZY51KEWSTzygTWM2OD1yLkCwOlg2\|ryP	NHHBXGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NVY3OCd-MkOwOlE3PjB:L3G+
T-cells	MY\GeY5kfGmxbjDhd5NigQ>?			Mm\OTY5pcWKrdHnvckBw\iCMQVuzM\|EhcW5iaIXtZY4hXCClZXzsd{BmgHC{ZYPzbY5oKEOGMzDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnMNk1{fGmvdXzheIVlKFOWQWS1ZUBxcG:\|cHjvdplt[XSrb36sJGlEPTB;MD6wNlPPxE1?	M2G5T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUSwOlQ5Lz5{M{W0NFY1QDxxYU6=
T-cells	NWnqS\|FuTnWwY4Tpc44h[XO\|YYm=			M1TiVmlvcGmkaYTpc44hd2ZiSlHLNk8yKGmwIHj1cYFvKFRiY3XscJMh\XiycnXzd4lv\yCFREOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDJSm5o[W2vYT3zeIlufWyjdHXkJHNVSVRzIIDoc5NxcG:{eXzheIlwdixiSVO1NF0xNjB\|Md88US=>	MmWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEC2OFgoRjJ\|NUSwOlQ5RC:jPh?=
Sf9	NIqxT4lHfW6ldHnvckBie3OjeR?=		M1zGRVEhcHJ?	NX:y[\|JrUW6qaXLpeIlwdiCxZjDoeY1idiCMQVuyJEg5OjhvMUGzNkkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzMYlv\mWldHXkJHNnQSClZXzsd{B2e2mwZzDFVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliSGTSSkBie3OjeTygT4k:OC5yMECx{txO	MkXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nki0PFQoRjJ\|Nk[4OFg1RC:jPh?=
Sf9	NFnGSGpHfW6ldHnvckBie3OjeR?=		NVfjcFgyOSCqch?=	NWO5TW1lUW6qaXLpeIlwdiCxZjDoeY1idiCMQVuxJEg5OzdvMUG0Nkkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzMYlv\mWldHXkJHNnQSClZXzsd{B2e2mwZzDFVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliSGTSSkBie3OjeTygT4k:OC5yMECy{txO	NYLNbVNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olg1QDRpPkKzOlY5PDh2PD;hQi=>
Sf9	NVnsPXMxTnWwY4Tpc44h[XO\|YYm=		NGnDO3gyKGi{	M1W0dWlvcGmkaYTpc44hd2ZiaIXtZY4hXFmNMjCoPFc{NTFzOEepJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lkh[2WubIOgeZNqdmdiRWHFSGVRTUeGWV\FW2xGKGG\|IIP1ZpN1emG2ZTDh[pRmeiBzIHjyJIJ6KEiWUl[gZZN{[XluIFvpQVAvODByNd88US=>	MkPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nki0PFQoRjJ\|Nk[4OFg1RC:jPh?=
Sf9	M1[3VmZ2dmO2aX;uJIF{e2G7		NUiwOFV2OSCqch?=	NWWwbIMxUW6qaXLpeIlwdiCxZjDoeY1idiCMQVuzJEg4QDFvMUGyOEkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzMYlv\mWldHXkJHNnQSClZXzsd{B2e2mwZzDFVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliSGTSSkBie3OjeTygT4k:OC5yMEOy{txO	NFrF[Yc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2PFQ5PCd-MkO2Olg1QDR:L3G+
CD34+	M1e5Z2Z2dmO2aX;uJIF{e2G7		Mk\mOFUhdWmwcx?=	M1;MNmlvcGmkaYTpc44hd2ZiSlHLNkBpd22xZHnt[ZIhcW5iaIXtZY4hS0R\|NDugZ4VtdHNic4Dpb4VlKGmwdH:gbJVu[W5id3jvcIUh[myxb3SgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDFVG8ucW6mdXPl[EBUXEGWLUWgdIhwe3Cqb4L5cIF1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiNEWgcYlveyCob3zsc5dm\CCkeTDFVG8h[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgNVUhdWmwczDifUBHSUOVIHHuZYx6e2m\|LDDJR\|UxRTBwNke3{txO	MmDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1N\|MoRjJ2NEG3OVM{RC:jPh?=
BA/F3	M2\SOGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{[5elczKGi{cx?=	NGi5UmhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochXEWOLVrBT\|Eh[W[2ZYKgO\|IhcHK\|IHL5JINmdGxidHn0[ZIh\2yxIHHzd4F6	NH3Yd289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1PFUzOSd-Mk[yOVg2OjF:L3G+
BA/F3	M2O0NWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NIjJUZQ4OiCqcoO=	MmLyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJHRGVC2MQVuyJIFnfGW{IEeyJIhzeyCkeTDj[YxtKHSrdHXyJIdtdyCjc4PhfS=>	MkjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
TALL-1	MWjGeY5kfGmxbjDhd5NigQ>?	Mn;5NUB2VQ>?	MYSzJIhzew>?	M1P1WGlvcGmkaYTpc44hd2ZiSlHLN{BqdiCqdX3hckBVSUyOLUGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCLTD2yJIlv\HWlZXSgV3RCXDVicHjvd5Bpd3K7bHH0bY9vKGG2IEGgeW0heHKnaX7jeYJifGWmIH\vdkA{KGi{czDmc4xtd3enZDDifUBKVC1{IHnu[JVkfGmxbjDt[YF{fXKnZDDh[pRmeiB\|MDDtbY5{KGK7IHntcZVvd2Kub4T0bY5o	Mn7sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
OCL-AML5	NX;mRpJpTnWwY4Tpc44h[XO\|YYm=	M{nNclEhfU1?	NXLGRmtGOyCqcoO=	NUHReWFUUW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKE:FTD3BUWw2KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gS20uS1OIIHnu[JVk\WRiU2TBWFUheGixc4Doc5J6dGG2aX;uJIF1KDFidV2gdJJmcW6ldXLheIVlKG[xcjCzJIhzeyCob3zsc5dm\CCkeTDHUU1EW0ZiaX7keYN1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdITpcoc>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3OEWyNUc,OjZ{NUi1NlE9N2F-
CD34+	NGC2W3pHfW6ldHnvckBie3OjeR?=			MVLJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gR2Q{PCtiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBGWE9vbXXkbYF1\WRiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxRTBwMEC4{txO	NYLZR4VERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5Nlc1OjNpPkK2PVI4PDJ\|PD;hQi=>
PBMC	M{[2WWZ2dmO2aX;uJIF{e2G7			MnKxTY5pcWKrdHnvckBw\iCMQVuxJIlvKGi3bXHuJHBDVUNiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBKVC14LXnu[JVk\WRiTVPQNUB{\WO{ZYTpc44tKEmFNUC9NE4xPM7:TR?=	NHTCbGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkmyO\|QzOyd-Mk[5Nlc1OjN:L3G+
PBMC	NYDw[4dTTnWwY4Tpc44h[XO\|YYm=			M3;K[WlvcGmkaYTpc44hUUxvNz3pcoRkfWWmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBRSk2FIHPlcIx{KGK7IH\sc5ch[3m2b33leJJ6NCCLQ{WwQVAvPDR6zszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl{N{SyN{c,OjZ7Mke0NlM9N2F-
Sf21	NI[0[HFHfW6ldHnvckBie3OjeR?=		M3rDPFYxKG2rboO=	NF;l[3ZKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFrBT\|Ih\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIGXsbYdpfC2FQVfBS2FKTVSGS1XZXXRXU0RicHjvd5Bpd3K7bHH0bY9vKHC{ZT3pcoN2[mG2ZXSgZoVnd3KnIIP1ZpN1emG2ZTDh[IRqfGmxbjDhcoQhdWWjc4Xy[YQh[W[2ZYKgOlAhdWmwczDifUBNSU6FRTDk[ZRm[3Srb36gcYV1cG:mLDDJR\|UxRTBwMECz{txO	NELwOYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzO\|M2QSd-MkexN\|c{PTl:L3G+
Sf21	NX;sd2NsTnWwY4Tpc44h[XO\|YYm=		NXeye5k1OSCqch?=	NEnw[mJKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIFOteIVzdWmwYXygOmhqey22YXfn[YQhUkGNMjCoPFA5KHSxIHXu[EBidWmwbzDhZ4lleyliZYjwdoV{e2WmIHnuJHNnOjFiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgNUBpeiCrbjDwdoV{\W6lZTDv[kBCXFBiYomgWHIuTlKHVDDhd5NigSxiSVO1NF0xNjByNEJOwG0>	MmK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3NUWyPFQoRjJ5NUW1Nlg1RC:jPh?=
BaF3	MnHOSpVv[3Srb36gZZN{[Xl?			Ml35TY5pcWKrdHnvckBw\iCMQVuyJHY3OTeIIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViQnHGN{Bk\WyuczDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImsJGVEPTB;MD6xPFbPxE1?	M{C0cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUW1Nlg1Lz5{N{W1OVI5PDxxYU6=
HEL 92.1.7	MWPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NG\kN3Y{KGSjeYO=	NF3ZcJBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGhGVCB7Mj6xMlch[2WubIOgZZN{\XO\|ZXSgZZMhfmmjYnzlJINmdGy\|IH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCZU2StNUBie3OjeTygTWM2OD1zND63{txO	Mm\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3NUWyPFQoRjJ5NUW1Nlg1RC:jPh?=
HCC827	NUTtW4N[TnWwY4Tpc44h[XO\|YYm=	M1GzblMxKHWP	NHPGSoozPCCqcoO=	NWXD[lFHUW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKGenZnn0bY5q[i2{ZYPpd5RidnRiSFPDPFI4KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gV3RCXDNicHjvd5Bpd3K7bHH0bY9vKGG2IGm3NFUhe2m2ZTDheEA{OCC3TTDt[YF{fXKnZDDh[pRmeiB{NDDodpMh[nlid3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqew>?	NXrmSIRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1OVUzQDRpPkK3OVU2Ojh2PD;hQi=>
HCC827	NHPSfmxHfW6ldHnvckBie3OjeR?=	NV\Kd2dvOzBidV2=	NXn0V\|NNOjRiaILz	MkK4TY5pcWKrdHnvckBw\iCMQVuyJIlvKHerbHSteJlx\SCqdX3hckBJS0N6MkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhYTdyNTDzbZRmKGG2IEOwJJVOKG2nYYP1doVlKGGodHXyJFI1KGi{czDifUB4\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz	M321O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUW1Nlg1Lz5{N{W1OVI5PDxxYU6=
HEL	NVvxVVhHSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Ml3iOFghcHK\|	MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFjFUEBk\WyuczDoZZJjd3KrbnegTmFMOiCYNkG3SkBufXSjboSgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1{Lk[y{txO	M4HBXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVM2Lz5{N{e3OFE{PTxxYU6=
K562	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NYHHd\|dlPDhiaILz	MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yOC5\|zszN	M3TGR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVM2Lz5{N{e3OFE{PTxxYU6=
MOLT4	NYK5V\|ZySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFGwV3I1QCCqcoO=	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTGS0JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OTVwON88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGzOUc,Ojd5N{SxN\|U9N2F-
NCI-H23	NV;1RWRySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			M3z4bWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOyClZXzsd{Bp[XKkb4LpcochU1KDUzDHNVJEKG23dHHueEBifA>?	NEflS5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECzPFk1OCd-MkiwN\|g6PDB:L3G+
NCI-H358	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NXL5bok3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDN3ODDj[YxteyCqYYLic5JqdmdiS2LBV{BIOTKFIH31eIFvfCCjdB?=	M4nYeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4PVQxLz5{OECzPFk1ODxxYU6=
A673	MWPxTHRUKGG\|c3H5			NWjUW4RQeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	NHXyT2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NGHiRnRyUFSVIHHzd4F6			NXjofY41eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NGDTRYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MnHldWhVWyCjc4PhfS=>			MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	NGq4W5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	MYTxTHRUKGG\|c3H5			MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	Mn7KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
HeLa	NHfyeW9HfW6ldHnvckBie3OjeR?=	MWKwMlEhfG9iMTD1US=>	Ml;YNUBpeg>?	MVLJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gV3RCXDVicHjvd5Bpd3K7bHH0bY9vKGG2IECuNUB1dyBzIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdDDhcoFtgXOrcx?=	NV3KV4VFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyOFMyPThpPkOwNlQ{OTV6PD;hQi=>
HeLa	NYrXeYlqTnWwY4Tpc44h[XO\|YYm=	Mo[3NE4yKHSxIEGgeW0>	M4nDfFEhcHJ?	MkjMTY5pcWKrdHnvckBw\iCMQVuyJIlvKGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gTmFMOiCyaH;zdIhwenmuYYTpc44h[XRiMD6xJJRwKDFidV2gZYZ1\XJiMTDodkBjgSCrbX31co9jdG:2IHHuZYx6e2m\|	NFjBR5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK0N\|E2QCd-M{CyOFMyPTh:L3G+
Sf9	MVvGeY5kfGmxbjDhd5NigQ>?		NUXWU5V7OSCqch?=	NFLPRnlKdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgLFgzQCC2bzCxNVMzKHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDFVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxRTBwMECyPO69VQ>?	MkPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB6M{OxOVgoRjNyOEOzNVU5RC:jPh?=
Sf9	NIXsUmVHfW6ldHnvckBie3OjeR?=		MnvINUBpeg>?	NXTrXGpEUW6qaXLpeIlwdiCxZjDoeY1idiCMQVuxJEg5OzdidH:gNVE1OiC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegSXFGTEWSRVfEXWZGX0yHIHHzJJN2[nO2cnH0[UBi\nSncjCxJIhzKGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OD1yLkCwN\|PPxE1?	NVjGNItIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C4N\|MyPThpPkOwPFM{OTV6PD;hQi=>
HEL	M1qwXWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHPyTZA1QCCqcoO=	MlnZV5lv\XKpaYP0bYMh[W62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBJTUxiY3XscJMhcGG{Yn;ybY5oKEqDS{KgWlYyP0ZibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMhcW5icILld4Vv[2Vib3[gV2FJSSCkeTDNWHQh[XO\|YYmsJGlEPTB;MD6z{txO	NUnhXVZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5NFEzODhpPkOwPVAyOjB6PD;hQi=>
K562	M{Lz[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MkPVOFghcHK\|	M4nTWXN6dmW{Z3nzeIlkKGGwdHnwdo9tcW[ncnH0bZZmKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gT\|U3OiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIlvKHC{ZYPlcoNmKG:oIGPBTGEh[nliTWTUJIF{e2G7LDDJR\|UxRTFwMEROwG0>	NUG4SVdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5NFEzODhpPkOwPVAyOjB6PD;hQi=>
MOLT4	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXe0PEBpenN?	NHv5WWpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUHQ1KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE2NjkQvF2=	NYrrPI5ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5NFEzODhpPkOwPVAyOjB6PD;hQi=>
HEL	Mo\3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnTrOFghcHK\|	NYH1TJZPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBJTUxiY3XscJMhcGG{Yn;ybY5oKEqDS{KgWlYyP0ZibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTF6LkdOwG0>	M3XDVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUCxNlA5Lz5\|MEmwNVIxQDxxYU6=
K562	MmfuRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXW0PEBpenN?	MkHRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNNU[yJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUKzMlLPxE1?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODlyMUKwPEc,OzB7MEGyNFg9N2F-
A549	NIH2b3FHfW6ldHnvckBie3OjeR?=	NWf1W4V1QDBidH:gOFAxKG6P	M{\RU\|YhcHK\|	Ml74TY5pcWKrdHnvckBw\iCKRFHDNkBqdiCqdX3hckBCPTR7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIFk\XS7bDDobZN1d26nIFi0JIxmfmWuIHH0JFgxKHSxIESwNEBvVSCjZoTldkA3KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODlyMUKwPEc,OzB7MEGyNFg9N2F-
A549	MnjQSpVv[3Srb36gZZN{[Xl?	Mn7PPFAhfG9iNECwJI5O	NWHzUWppPiCqcoO=	MmO1TY5pcWKrdHnvckBw\iCKRFHDNUBqdiCqdX3hckBCPTR7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIFk\XS7bDDobZN1d26nIFi0JIxmfmWuIHH0JFgxKHSxIESwNEBvVSCjZoTldkA3KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NIHOV3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEmwNVIxQCd-M{C5NFEzODh:L3G+
A549	MYXGeY5kfGmxbjDhd5NigQ>?	MXS4NEB1dyB2MECgcm0>	NYW5c21UPiCqcoO=	NFLxSHBKdmirYnn0bY9vKG:oIFjERWM{KGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[WOndInsJIhqe3SxbnWgTFQhdGW4ZXygZZQhQDBidH:gOFAxKG6PIHHmeIVzKDZiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NYfQeGVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5NFEzODhpPkOwPVAyOjB6PD;hQi=>
A549	M{\SSmZ2dmO2aX;uJIF{e2G7	NHfme\|g5OCC2bzC0NFAhdk1?	MXW2JIhzew>?	NWLTVGEyUW6qaXLpeIlwdiCxZjDISGFEPiCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGGlZYT5cEBidHCqYTD0eYJ2dGmwIHzleoVtKGG2IEiwJJRwKDRyMDDuUUBi\nSncjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	M4G2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUCxNlA5Lz5\|MEmwNVIxQDxxYU6=
HEL	M4XDUWZ2dmO2aX;uJIF{e2G7	MnXrNVAxKG2pL3vn	M3q4fVUh\GG7cx?=	MlvDSJJ2\yCuZY\lcEBqdiC2dX3vdkBw\iCEQVzCM4MhdnVibX;1d4UhgGWwb3fyZYZ1\WRid3n0bEBJTUxiY3XscJMh[XRiMUCwJI1oN2upL3ThfUwhcXBiYXTtbY5qe3SncnXkJIZweiB3IHThfZMh[W6mIH3lZZN2emWmIEGgbJIheG:\|dD3sZZN1KGSxc3WgZpkhVENvTWOvUXMh[W6jbInzbZM>	NYrCRodQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5NFEzODhpPkOwPVAyOjB6PD;hQi=>
Sf9	MXvGeY5kfGmxbjDhd5NigQ>?		NGTqdmE{OCC\|ZXPz	MkDwTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIHjlfIFpcXO2aXTpcoUhfGGpZ3XkJGpCUzJiSlixJINifGGueYTpZ{Bld22jaX6gLFg{PSC2bzCxNVMzKHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KHW\|aX7nJHR6ejZicHXweIll\SCjczDzeYJ{fHKjdHWgbY5kfWKjdHXkJIZweiB\|MDDz[YN{KHWwZHXyJJNp[WurbnegZ49v\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEGgbJIhNCCLQ{WwQVAvODByNt88US=>	NWXmV3EyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C5PFE2PzhpPkOwPVgyPTd6PD;hQi=>
Sf21	NWHjSpFuTnWwY4Tpc44h[XO\|YYm=		NVHHOm9MOSCqch?=	M3HUNmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDldIl1d3CnLYTh[4dm\CCMQVuyJEg5OjhidH:gNVE{OiC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoMkGgbY5{\WO2IHPlcIx{KHW\|aX7nJGVSTUSHUFXHSHlHTVeORTDhd{B{fWK\|dILheIUh[W[2ZYKgNUBpeiCkeTDoc41w\2WwZX;1d{B1cW2nLYLld49tfmWmIH\seY9z\XOlZX7j[UBie3OjeTygTWM2OD1yLkCwNljPxE1?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODl6MUW3PEc,OzB7OEG1O\|g9N2F-
Sf9	NXzNZ5g2TnWwY4Tpc44h[XO\|YYm=		NXja[IlOOzBic3Xjdy=>	NHzM[GlKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IF6teIVzdWmwYXygbIV5[Wirc4Tp[Ilv\SC2YXfn[YQhUkGNMTDKTFEh[2G2YXz5eIlkKGSxbXHpckApQDV2IITvJFEyPTRicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkmgZ4VtdHNidYPpcochXHm{NjDw[ZB1cWSnIHHzJJN2[nO2cnH0[UBqdmO3YnH0[YQh\m:{IEOwJJNm[3NidX7k[ZIhe2ija3nu[{Bkd26maYTpc44hdWWjc4Xy[YQh[W[2ZYKgNUBpeiBuIFnDOVA:OC5yMEVOwG0>	M1fpdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixOVc5Lz5\|MEm4NVU4QDxxYU6=
Sf9	NVPRS3pkTnWwY4Tpc44h[XO\|YYm=			NIXqeItDcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJJJm[2:vYnnuZY51KE5vdHXycYlv[WxiaHX4ZYhqe3SrZHnu[UB1[WepZXSgTmFMOiCMSEGgZ4F1[Wy7dHnjJIRwdWGrbjCoPFM2KHSxIEGxN\|IhemW\|aXT1[ZMqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliY3XscJMh[XO\|ZYPz[YQh[XNiZHnzd49kcWG2aX;uJINwdnO2YX70JIJ6KHO3cn\hZ4UheGyjc33vckBz\XOxbnHuZ4Uh[XO\|YYmsJGtlRTBwMEK4Nu69VQ>?	NHPhTZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEm4NVU4QCd-M{C5PFE2Pzh:L3G+
Sf9	M1mwNmZ2dmO2aX;uJIF{e2G7		M1zJelMxKHOnY4O=	NXq5RmVWUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDDMZRmem2rbnHsJIhmgGGqaYP0bYRqdmVidHHn[4VlKEqDS{OgTmgyKGOjdHHsfZRq[yCmb33hbY4hMDhzMTD0c{AyOTJ2IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JINmdGy\|IIXzbY5oKFS7ck[gdIVxfGmmZTDhd{B{fWK\|dILheIUhcW6ldXLheIVlKG[xcjCzNEB{\WO\|IIXu[IVzKHOqYXvpcoch[2:wZHn0bY9vKG2nYYP1doVlKGGodHXyJFEhcHJiLDDJR\|UxRTBwMEWx{txO	M4TVXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixOVc5Lz5\|MEm4NVU4QDxxYU6=
HEL	NI\6d41CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGjLNlU{KGSjeYO=	NIT3cHdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGhGVCClZXzsd{Bp[XKkb4LpcochUkGNMjDWOlE4TiCvdYThcpQhdWWjc4Xy[YQh[W[2ZYKgN{Bl[Xm\|IHL5JGNEUzhiYYPzZZktKEmFNUC9O{43OzoQvF2=	M3HnV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUixOVc5Lz5\|MEm4NVU4QDxxYU6=
insect cells	NEn2fZZHfW6ldHnvckBie3OjeR?=		M{n4[FExKG2rboO=	M2LsNWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGpCUzFiKEi2OkB1dyBzMUW0JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIF\JWGMudGGkZXzl[EBEPi2NS1jUSGRIYU2STWPQS3ZCNU6KIIDldJRq\GViYYOgd5Vje3S{YYTlJIFnfGW{IEGwJI1qdnNiaX6gdJJme2WwY3Wgc4YhPSCvTTDBWHAh[nliY3HsbZBmeiCvb3LpcIl1gSC\|aHnmeEBie3OjeTygTWM2OD1yLkCy{txO	NFLtcWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MkK5O\|c1Oyd-M{KyPVc4PDN:L3G+
insect cells	MkjNSpVv[3Srb36gZZN{[Xl?		Mk\MNVAhdWmwcx?=	M17lUGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGpCUzJiKEizNUB1dyBzMUOyJJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIEXGRW0udGGkZXzl[EBITUWSTGnXV2ZRSUuNSz3OTFIheGWydHnk[UBieyC\|dXLzeJJifGViYX\0[ZIhOTBibXnud{BqdiCycnXz[Y5k\SCxZjC1JI1OKEGWUDDifUBk[WyrcHXyJI1w[mmuaYT5JJNpcW[2IHHzd4F6NCCLQ{WwQVAvODMQvF2=	MnHBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzJ{OUe3OFMoRjN{Mkm3O\|Q{RC:jPh?=
BAF3	M3:wNmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYXNWmJXPDhiaILz	MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochUkGNMjDWOlE4TiCvdYThcpQh[W[2ZYKgOFghcHK\|IHL5JGNmdGyWaYTldmdtdyCjc4PhfUwhUUN3ME2wMlEzPs7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxO\|g6QTRzLze+R4hGVUKOPD;hQi=>

Click to View More Cell Line Experimental Data

Protocol (from reference)

References

[1] Alfonso Quintás-Cardama, et al. Blood . 2010 Apr 15;115(15):3109-17.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight	404.36
Formula	C₁₇H₁₈N₆.H₃O₄P
CAS No.	1092939-17-7
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02596347	Completed	Procedure: Blood draw\|Procedure: bronchoscopy	Chronic Beryllium Disease (CBD)\|Beryllium Sensitization (BeS)	National Jewish Health	April 2015	--
NCT01787552	Completed	Drug: LDE225\|Drug: INC424	Primary Myelofibrosis\|Thrombocytosis\|Essential Thrombocythemia\|Polycythemia Vera\|Myeloproliferative Disorders\|Bone Marrow Diseases\|Hematologic Diseases\|Blood Coagulation Disorders\|Blood Platelet Disorders\|Hemorrhagic Disorders	Novartis Pharmaceuticals\|Novartis	May 8 2013	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):